Search results
Results from the WOW.Com Content Network
[36] [37] [38] By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. [ 35 ] [ 36 ] Motley Fool , discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below ...
On May 2, 2019, shareholders of the company approved the change of the company's name from Horizon Pharma plc to Horizon Therapeutics plc. [ 13 ] In January 2020 – after showing very strong PhIII data – it was approved for the treatment of thyroid eye disease (TED), a rare vision-threatening disease that previously had no FDA-approved ...
Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, [1] especially in relation to approaches making use of new cell therapy or gene therapy developments. [2]
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
For premium support please call: 800-290-4726 more ways to reach us
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial.
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. [ 3 ]
Price Action: VRTX stock is down 13.4% at $387.37 at last check Thursday. Read Next: Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges